SenesTech, Inc. (SNES) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. SenesTech, Inc. is a smaller reporting company developing and commercializing proprietary fertility control technology for managing animal pest populations (rats and mice). Key products include ContraPest, Evolve (launched Jan 2024), and Evolve Mouse (launched May 2024). The company operates in one segment and is headquartered in Phoenix, Arizona.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $482,000 | $360,000 | $1,356,000 | $898,000 |
| Gross Profit | $315,000 | $176,000 | $699,000 | $410,000 |
| Gross Margin | 65.4% | 48.8% | 51.5% | 45.6% |
| Net Loss | $(1,513,000) | $(1,947,000) | $(4,929,000) | $(5,977,000) |
| Cash & Equivalents (End of Period) | $2,518,000 | $2,145,000 | $2,518,000 | $2,145,000 |
| Accumulated Deficit | $(134.8M) | $(128.2M) | $(134.8M) | $(128.2M) |
| Notes Payable (Total) | $223,000 | $189,000 | $223,000 | $189,000 |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 revenue increased 34% year-over-year, driven primarily by the launch of the "Evolve" product line, which accounted for approximately 68% of Q3 revenue. This offset a decline in units sold for the legacy ContraPest product.
- Margin Expansion: Gross margin improved significantly to 65.4% in Q3 2024 from 48.8% in Q3 2023, attributed to a favorable product mix shift toward Evolve and lower cost of sales relative to revenue.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 19% in Q3 2024 compared to the prior year, largely due to lower personnel costs (reduced headcount) and decreased stock-based compensation.
- Capital Structure: The company executed a 1-for-10 reverse stock split in July 2024. In August 2024, the company raised approximately $2.0 million through a warrant inducement transaction, issuing new warrants and reducing exercise prices to induce exercise of existing warrants.
Outlook, Risks, and Management Commentary
- Liquidity & Going Concern: Management states that cash on hand ($2.5M) combined with anticipated revenue is sufficient to fund operations for at least the next four months. The company explicitly notes it will require additional financing to achieve revenue targets and continue operations beyond this period.
- Going Concern Qualification: The filing reiterates substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and an accumulated deficit of $134.8 million. Continued losses are expected for the foreseeable future.
- Financing Needs: The company plans to raise additional capital through equity or debt financing. Failure to secure funding could force the company to delay, limit, or terminate commercialization efforts.
- Subsequent Events: Following the quarter-end, the company issued 12,802 shares under its At-The-Market (ATM) facility for gross proceeds of $38,000.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next financing round given the stated four-month liquidity horizon.
- Product Mix Sustainability: Confirm if the high gross margins from the new "Evolve" product line are sustainable as the company scales production and sales.
- Dilution Risk: Review the impact of the recent warrant inducement and the outstanding 1.3 million warrants on future share count and dilution.
- Regulatory Status: Monitor the progress of state-level registrations for Evolve and Evolve Mouse, as sales are currently limited to specific jurisdictions.
- Customer Concentration: Note that distributors accounted for 41% of revenue in Q3 2024, with one distributor representing 14% of revenue.